REG - Morgan Stanley Takeda Pharma.Co.Ltd - Form 8.5 (EPT/NON-RI) - TAKEDA PHARMACEUTICAL
RNS Number : 6477WMorgan Stanley02 August 2018
FORM 8.5 (EPT/NON-RI)
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN
EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)
Rule 8.5 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Name of exempt principal trader:
Morgan Stanley MUFG Securities Co., Ltd.
(b) Name of offeror/offeree in relation to whose relevant securities this form relates:
Use a separate form for each offeror/offeree
Takeda Pharmaceutical Company Limited
(c) Name of the party to the offer with which exempt principal trader is connected:
Shire plc
(d) Date position held/dealing undertaken:
For an opening position disclosure, state the latest practicable date prior to the disclosure
01 AUGUST 2018
(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to the offer?
If it is a cash offer or possible cash offer, state "N/A"
YES - Shire plc
2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER
If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.
(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
Class of relevant security:
Ordinary
Interests
Short positions
Number
%
Number
%
(1) Relevant securities owned and/or controlled:
2,448,779
0.31
10,237,684
1.31
(2) Cash-settled derivatives:
10,019,934
1.28
2,106,800
0.27
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:
0
0.00
0
0.00
TOTAL:
12,468,713
1.59
12,344,484
1.58
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
(b) Rights to subscribe for new securities (including directors' and other employee options)
Class of relevant security in relation to which subscription right exists:
N/A
Details, including nature of the rights concerned and relevant percentages:
N/A
3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of relevant security
Purchases/sales
Total number of securities
Highest price per unit paid/received
Lowest price per unit paid/received
Ordinary
PURCHASES
1,088,554
4,844.0606 JPY
4,629.7157 JPY
Ordinary
SALES
1,483,768
4,845.0000 JPY
4,629.7157 JPY
(b) Cash-settled derivative transactions
Class of relevant security
Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities
Price per unit
Ordinary
CFD
LONG
300
4837.0000 JPY
Ordinary
CFD
SHORT
700
4771.7142 JPY
Ordinary
CFD
SHORT
19100
4797.2707 JPY
Ordinary
CFD
SHORT
51900
4790.6551 JPY
Ordinary
CFD
LONG
3300
4827.0303 JPY
Ordinary
CFD
LONG
9700
4802.2989 JPY
Ordinary
CFD
SHORT
5400
4764.1481 JPY
Ordinary
CFD
SHORT
400
4768.0000 JPY
Ordinary
CFD
LONG
400
4838.0000 JPY
Ordinary
CFD
SHORT
4100
4839.5609 JPY
Ordinary
CFD
LONG
2700
4844.0000 JPY
Ordinary
CFD
SHORT
2800
4844.0000 JPY
Ordinary
CFD
SHORT
6800
4844.0000 JPY
Ordinary
CFD
SHORT
800
4778.0000 JPY
Ordinary
CFD
LONG
400
4808.0000 JPY
Ordinary
CFD
SHORT
1300
4768.0000 JPY
Ordinary
CFD
LONG
2900
4790.1724 JPY
Ordinary
CFD
LONG
1600
4835.5625 JPY
Ordinary
CFD
SHORT
3300
4773.1115 JPY
Ordinary
CFD
SHORT
5900
4804.4947 JPY
Ordinary
CFD
LONG
20000
4837.7450 JPY
Ordinary
CFD
LONG
100
4780.0000 JPY
Ordinary
CFD
SHORT
1300
4768.0000 JPY
Ordinary
CFD
SHORT
6700
4844.0000 JPY
Ordinary
CFD
LONG
22500
4839.5306 JPY
Ordinary
CFD
SHORT
2700
4844.0000 JPY
Ordinary
CFD
LONG
1900
4836.5789 JPY
Ordinary
CFD
SHORT
1500
4844.0000 JPY
Ordinary
CFD
SHORT
100
4773.0000 JPY
Ordinary
CFD
LONG
100
4844.0000 JPY
Ordinary
CFD
LONG
100
4773.0000 JPY
Ordinary
CFD
SHORT
4100
4781.1707 JPY
Ordinary
CFD
LONG
900
4844.0000 JPY
Ordinary
CFD
SHORT
900
4844.0000 JPY
Ordinary
CFD
SHORT
1000
4844.0000 JPY
Ordinary
CFD
LONG
900
4844.0000 JPY
Ordinary
CFD
LONG
1000
4748.0000 JPY
Ordinary
CFD
LONG
2300
4794.0000 JPY
Ordinary
CFD
SHORT
300
4785.0000 JPY
Ordinary
CFD
LONG
500
4794.0000 JPY
Ordinary
CFD
SHORT
500
4785.0000 JPY
Ordinary
CFD
LONG
410960
4788.7172 JPY
Ordinary
CFD
SHORT
200
4775.0000 JPY
Ordinary
CFD
SHORT
6400
4748.2950 JPY
Ordinary
CFD
SHORT
3600
4748.2950 JPY
Ordinary
CFD
LONG
3200
4675.0000 JPY
Ordinary
CFD
SHORT
400
4730.2500 JPY
Ordinary
CFD
SHORT
8800
4775.4423 JPY
Ordinary
CFD
SHORT
1600
4775.4423 JPY
Ordinary
CFD
LONG
1000
4806.8000 JPY
Ordinary
CFD
LONG
3300
4697.2727 JPY
Ordinary
CFD
SHORT
140000
4844.0606 JPY
Ordinary
CFD
LONG
3154
4629.7157 JPY
Ordinary
CFD
LONG
50300
4800.1809 JPY
Ordinary
CFD
SHORT
50300
4800.1809 JPY
Ordinary
CFD
LONG
168700
4795.4994 JPY
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of relevant security
Product description e.g. call option
Writing, purchasing, selling, varying etc.
Number of securities to which option relates
Exercise price per unit
Type
e.g. American, European etc.
Expiry date
Option money paid/ received per unit
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
(ii) Exercise
Class of relevant security
Product description
e.g. call option
Exercising/ exercised against
Number of securities
Exercise price per unit
N/A
N/A
N/A
N/A
N/A
(d) Other dealings (including subscribing for new securities)
Class of relevant security
Nature of dealing
e.g. subscription, conversion
Details
Price per unit (if applicable)
N/A
N/A
N/A
N/A
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"
None
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"
None
(c) Attachments
Is a Supplemental Form 8 (Open Positions) attached?
NO
Date of disclosure:
02 AUGUST 2018
Contact name:
Craig Horsley
Telephone number:
+44(141) 245 7736
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDFEOEAEPAEDPPEFF
Recent news on Takeda Pharmaceutical Co
See all newsREG - Malin Corp PLC - Malin Announces 2021 Full Year Results
AnnouncementREG - Takeda Pharma.Co.Ltd Shire plc - Confirmation of post-offer intention statements
AnnouncementREG - Morgan Stanley&CoLLC Takeda Pharma.Co.Ltd - Form 8.5 (EPT/RI) - Replacement of Takeda
AnnouncementREG - Takeda Pharma.Co.Ltd Shire plc - Statement re Applicable Exchange Rate
AnnouncementREG - Morgan Stanley Takeda Pharma.Co.Ltd - Form 8.5 (EPT/NON-RI) - Replacement of Takeda
Announcement